Incidence and Burden of Herpes Zoster in Sweden: A Regional Population-Based Register Study
ConclusionHZ and PHN risk in Sweden is comparable to that in other European countries prior to implementing HZ national vaccination programs. Municipal differences suggest that the lifetime risk of HZ in Sweden is at least 36.5%.Clinical Trial RegistrationNCT Number (www.clinicaltrials.gov).Graphical Abstract
Source: Infectious Diseases and Therapy - Category: Infectious Diseases Source Type: research
More News: Autoimmune Disease | Brain | Cardiology | Cardiovascular | Clinical Trials | Databases & Libraries | Heart | Herpes | Infectious Diseases | Neurology | Pain | Primary Care | Shingles (Herpes Zoster) Vaccine | Study | Sweden Health | Vaccines | Varicella-Zoster Virus Vaccine